KR102498901B1 - Cd200 돌연변이체 및 그의 용도 - Google Patents

Cd200 돌연변이체 및 그의 용도 Download PDF

Info

Publication number
KR102498901B1
KR102498901B1 KR1020187035514A KR20187035514A KR102498901B1 KR 102498901 B1 KR102498901 B1 KR 102498901B1 KR 1020187035514 A KR1020187035514 A KR 1020187035514A KR 20187035514 A KR20187035514 A KR 20187035514A KR 102498901 B1 KR102498901 B1 KR 102498901B1
Authority
KR
South Korea
Prior art keywords
val
thr
leu
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187035514A
Other languages
English (en)
Korean (ko)
Other versions
KR20190003761A (ko
Inventor
필립 헉슬리
조셉 쉐리단
조나단 힐
Original Assignee
두센티스 바이오테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 두센티스 바이오테라퓨틱스 리미티드 filed Critical 두센티스 바이오테라퓨틱스 리미티드
Priority to KR1020237004504A priority Critical patent/KR102689460B1/ko
Publication of KR20190003761A publication Critical patent/KR20190003761A/ko
Application granted granted Critical
Publication of KR102498901B1 publication Critical patent/KR102498901B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187035514A 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도 Active KR102498901B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237004504A KR102689460B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
GB1608197.8 2016-05-10
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004504A Division KR102689460B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20190003761A KR20190003761A (ko) 2019-01-09
KR102498901B1 true KR102498901B1 (ko) 2023-02-10

Family

ID=56297468

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187035514A Active KR102498901B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도
KR1020237004504A Active KR102689460B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237004504A Active KR102689460B1 (ko) 2016-05-10 2017-05-10 Cd200 돌연변이체 및 그의 용도

Country Status (15)

Country Link
US (1) US11203628B2 (https=)
EP (1) EP3455247A1 (https=)
JP (1) JP6997767B2 (https=)
KR (2) KR102498901B1 (https=)
CN (1) CN109219614B (https=)
AU (1) AU2017264825B2 (https=)
BR (1) BR112018073280A2 (https=)
CA (1) CA3023601A1 (https=)
EA (1) EA201892554A1 (https=)
GB (1) GB201608197D0 (https=)
IL (1) IL262846B2 (https=)
MX (1) MX386295B (https=)
SG (1) SG11201809677XA (https=)
WO (1) WO2017194941A1 (https=)
ZA (1) ZA201807079B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
AU2023265174A1 (en) * 2022-05-06 2024-12-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
CN119365483A (zh) * 2022-05-06 2025-01-24 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522867A (ja) 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
KR20130108481A (ko) * 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
CN102448982B (zh) * 2009-03-31 2018-04-20 华盛顿大学 用于调节靶细胞上补体调节蛋白的活性的组合物和方法
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522867A (ja) 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００

Also Published As

Publication number Publication date
US11203628B2 (en) 2021-12-21
BR112018073280A2 (pt) 2019-03-19
EA201892554A1 (ru) 2019-04-30
US20190367580A1 (en) 2019-12-05
GB201608197D0 (en) 2016-06-22
CA3023601A1 (en) 2017-11-16
IL262846A (en) 2018-12-31
KR20230025937A (ko) 2023-02-23
IL262846B2 (en) 2023-02-01
KR102689460B1 (ko) 2024-07-26
NZ747665A (en) 2025-10-31
JP6997767B2 (ja) 2022-03-04
IL262846B (en) 2022-10-01
EP3455247A1 (en) 2019-03-20
AU2017264825A1 (en) 2018-11-15
SG11201809677XA (en) 2018-11-29
KR20190003761A (ko) 2019-01-09
CN109219614B (zh) 2022-05-24
AU2017264825B2 (en) 2021-04-08
CN109219614A (zh) 2019-01-15
ZA201807079B (en) 2019-07-31
MX2018013778A (es) 2019-08-01
WO2017194941A1 (en) 2017-11-16
JP2019518788A (ja) 2019-07-04
MX386295B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
KR102498901B1 (ko) Cd200 돌연변이체 및 그의 용도
JP2018519834A (ja) ヒトＦｃ受容体に結合する融合タンパク質
WO2012018616A2 (en) Polypeptides that bind trail-r1 and trail-r2
US20250026805A1 (en) Novel proteins
JP2025515191A (ja) 新規ｃｄ２００融合タンパク質
EA042608B1 (ru) Мутант cd200 и его применения
CN117295758A (zh) 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白
US20260116951A1 (en) Novel cd200 fusion proteins
US20260116946A1 (en) Novel cd200 fusion proteins
JP2025516364A (ja) 新規ｃｄ２００融合タンパク質
US12122813B2 (en) Fusion protein comprising an antigen binding domain and a cytokine trimer domain
KR20260007620A (ko) Cd200 융합 단백질

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4